Main Session
Sep
29
PQA 07 - Head and Neck Cancer, Lung Cancer/Thoracic Malignancies, and Nursing and Supportive Care
3677 - Clinical Study of Chemotherapy Plus Immunotherapy Combined with Local Liver Radiotherapy for Patients with Distant Metastatic Nasopharyngeal Carcinoma
Presenter(s)
Feng Jin, BS - Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou
Y. Yang1, and F. Jin2; 1Department of Head and Neck Oncology, Affiliated Tumor Hospital of Guizhou Medical University, GuiYang, China, China, 2Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Purpose/Objective(s):
To compare the efficacy of chemotherapy combined with immunotherapy and local liver radiotherapy (triple regimen) with chemotherapy plus immunotherapy alone in patients with distant metastatic nasopharyngeal carcinoma, and to preliminarily explore the clinical value of additional liver radiotherapy, so as to provide evidence for individualized treatment.Materials/Methods:
We retrospectively analyzed clinical data of 41 patients with liver-metastatic nasopharyngeal carcinoma treated in our department between 2017 and 2025 (study group). Efficacy data from recent phase III trials (CAPTAIN-1st, JUPITER-02, RATIONALE-309) of chemotherapy plus immunotherapy alone were used as historical controls. Tumor response was assessed by RECIST v1.1. Primary outcomes included objective response rate (ORR), median progression-free survival (mPFS), and 1-year and 3-year overall survival (OS) rates.Results:
1.Short-term efficacy: The ORR was 76% (31/41) in the study group, comparable to 70%–77% in historical controls. 2.Survival outcomes: With a median follow-up of 27 months, the study group achieved a median PFS of 21 months, which was longer than 10–15 months in controls. The 1-year OS rate was 93% and 3-year OS rate was 66.5%, both superior to historical controls (85%–87% and 64.5%, respectively). 3.Safety: Treatment-related adverse events were mainly gastrointestinal reactions, myelosuppression, and radiation-induced liver injury. Grade ?–? events occurred in 15 patients (36.59%), grade ? in 4 patients (9.76%), with no grade ? or higher adverse events. All adverse events were manageable and reversible after symptomatic treatment.Conclusion:
Compared with chemotherapy plus immunotherapy alone, the triple regimen including local liver radiotherapy shows promising survival benefits and acceptable short-term efficacy with a manageable safety profile in patients with liver-metastatic nasopharyngeal carcinoma. Although limited by the inherent bias of historical control, our results provide a novel therapeutic reference for the comprehensive management of liver-metastatic nasopharyngeal carcinoma. Further prospective studies with larger sample sizes and longer follow-up are warranted to validate these findings.